Om

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases. The company’s lead candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor being evaluated in multiple settings, including acute pancreatitis, acute kidney injury, and other severe inflammatory conditions. CalciMedica also develops an oral CRAC channel inhibitor program aimed at chronic inflammatory and immunologic diseases. Its current work centers on drug discovery and clinical development for conditions where inflammation and direct cellular injury drive high unmet medical need. Based in La Jolla, California, CalciMedica plays a specialized role in the biotechnology market by advancing a differentiated calcium-channel inhibition platform for acute and chronic disease areas.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I CALCIMEDICA MED ENDAVU: Køb CalciMedica ($CALC) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i CalciMedica, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.